Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ami Patel

Showing results (191-200 of 209) with videos related to

Pageof 21
Sort By:
Vaccine|May 21, 2025
DNA co-delivery of seasonal H1 influenza hemagglutinin nanoparticle vaccines with chemokine adjuvant CTACK induces potent immunogenicity for heterologous protection in vivoKevin Liaw, Kylie M Konrath, Abigail R Trachtman, et al.
Iscience|June 14, 2021
A novel mouse AAV6 hACE2 transduction model of wild-type SARS-CoV-2 infection studied using synDNA immunogensEbony N Gary, Bryce M Warner, Elizabeth M Parzych, et al.
Emerging Microbes & Infections|January 2, 2024
In vivo delivery of engineered synthetic DNA-encoded SARS-CoV-2 monoclonal antibodies for pre-exposure prophylaxis in non-human primatesAmi Patel, Kyle Rosenke, Elizabeth M Parzych, et al.
Cell Reports. Medicine|March 22, 2025
Modulation of lipid nanoparticle-formulated plasmid DNA drives innate immune activation promoting adaptive immunityNicholas J Tursi, Sachchidanand Tiwari, Nicole Bedanova, et al.
Cell Reports|January 29, 2022
Nucleic acid delivery of immune-focused SARS-CoV-2 nanoparticles drives rapid and potent immunogenicity capable of single-dose protectionKylie M Konrath, Kevin Liaw, Yuanhan Wu, et al.
Cell Reports|November 15, 2018
In Vivo Delivery of Synthetic Human DNA-Encoded Monoclonal Antibodies Protect against Ebolavirus Infection in a Mouse ModelAmi Patel, Daniel H Park, Carl W Davis, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 11, 2024
NCCN Guidelines® Insights: Systemic Mastocytosis, Version 3.2024Jason Gotlib, Aaron T Gerds, Peter Abdelmessieh, et al.
The Journal of Infectious Diseases|October 11, 2018
Protective Efficacy and Long-Term Immunogenicity in Cynomolgus Macaques by Ebola Virus Glycoprotein Synthetic DNA VaccinesAmi Patel, Emma L Reuschel, Kimberly A Kraynyak, et al.
Nature Communications|October 6, 2022
DNA-delivered antibody cocktail exhibits improved pharmacokinetics and confers prophylactic protection against SARS-CoV-2Elizabeth M Parzych, Jianqiu Du, Ali R Ali, et al.
The Lancet. Infectious Diseases|July 29, 2019
Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trialKayvon Modjarrad, Christine C Roberts, Kristin T Mills, et al.
Pageof 21

Showing results (191-200 of 209) with videos related to

Sort By:
Pageof 21
Vaccine|May 21, 2025
DNA co-delivery of seasonal H1 influenza hemagglutinin nanoparticle vaccines with chemokine adjuvant CTACK induces potent immunogenicity for heterologous protection in vivoKevin Liaw, Kylie M Konrath, Abigail R Trachtman, et al.
Iscience|June 14, 2021
A novel mouse AAV6 hACE2 transduction model of wild-type SARS-CoV-2 infection studied using synDNA immunogensEbony N Gary, Bryce M Warner, Elizabeth M Parzych, et al.
Emerging Microbes & Infections|January 2, 2024
In vivo delivery of engineered synthetic DNA-encoded SARS-CoV-2 monoclonal antibodies for pre-exposure prophylaxis in non-human primatesAmi Patel, Kyle Rosenke, Elizabeth M Parzych, et al.
Cell Reports. Medicine|March 22, 2025
Modulation of lipid nanoparticle-formulated plasmid DNA drives innate immune activation promoting adaptive immunityNicholas J Tursi, Sachchidanand Tiwari, Nicole Bedanova, et al.
Cell Reports|January 29, 2022
Nucleic acid delivery of immune-focused SARS-CoV-2 nanoparticles drives rapid and potent immunogenicity capable of single-dose protectionKylie M Konrath, Kevin Liaw, Yuanhan Wu, et al.
Cell Reports|November 15, 2018
In Vivo Delivery of Synthetic Human DNA-Encoded Monoclonal Antibodies Protect against Ebolavirus Infection in a Mouse ModelAmi Patel, Daniel H Park, Carl W Davis, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 11, 2024
NCCN Guidelines® Insights: Systemic Mastocytosis, Version 3.2024Jason Gotlib, Aaron T Gerds, Peter Abdelmessieh, et al.
The Journal of Infectious Diseases|October 11, 2018
Protective Efficacy and Long-Term Immunogenicity in Cynomolgus Macaques by Ebola Virus Glycoprotein Synthetic DNA VaccinesAmi Patel, Emma L Reuschel, Kimberly A Kraynyak, et al.
Nature Communications|October 6, 2022
DNA-delivered antibody cocktail exhibits improved pharmacokinetics and confers prophylactic protection against SARS-CoV-2Elizabeth M Parzych, Jianqiu Du, Ali R Ali, et al.
The Lancet. Infectious Diseases|July 29, 2019
Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trialKayvon Modjarrad, Christine C Roberts, Kristin T Mills, et al.
Pageof 21